A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
about
Routine versus selective antifungal administration for control of fungal infections in patients with cancerInterventions for preventing oral candidiasis for patients with cancer receiving treatmentAntifungal Prophylaxis in Immunocompromised PatientsAssociation of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemiaProphylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.Routine versus selective antifungal administration for control of fungal infections in patients with cancer.Canadian clinical practice guidelines for invasive candidiasis in adults.Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection ProphylaxisVoriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during ConstructionSteady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Tailored treatment of invasive fungal infections.Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients.Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapyAntifungal prophylaxis during treatment for haematological malignancies: are we there yet?Using antimicrobial adjuvant therapy in cancer treatment: a review.Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients.Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia.How to manage lung infiltrates in adults suffering from haematological malignancies outside allogeneic haematopoietic stem cell transplantation.What Is the Optimal Induction Therapy for Younger Fit Patients With AML?Acute Myeloid Leukemia: How Do We Measure Success?A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients.The predictive value of Aspergillus PCR testing on bronchoalveolar lavage fluid for early diagnosis of invasive pulmonary aspergillosis in hematologic patients.Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias.Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies.Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis.Use of antifungal agents in pediatric and adult high-risk areas.Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up.Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis.Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
P2860
Q24193817-675B601A-4E52-4744-8467-96F6830A0FE6Q24243005-946CF66E-78AA-4FAB-8C67-AFC7672DD205Q28074168-EA98D6D4-CF9E-4B1B-9A7B-3513B51580D4Q33723595-91F1601E-C530-43B2-A905-06757FDE3AA0Q33886231-AF134634-F1A5-4F9A-86EB-75F61EA0AD11Q33909375-8CA009C2-7475-4A54-9368-4CCC8A68DCCEQ34237335-A0486288-1298-4C21-9B70-CA87E2CEC16EQ35959480-2BBF4F6F-4B96-4D8D-8CE2-0B6998AE8B0BQ36406975-1EAFC19D-C967-476A-8A4F-6D1298BC7E2EQ36439034-099E4FD3-B5E8-4930-95D2-C9B95752E2D0Q36696390-6AC71559-E502-4CBB-BE47-D94C0A7C33DCQ36722762-A1E42420-2E25-4383-B262-9DDA68E397ACQ36969849-06536AC6-C36A-4696-ADA2-ACBBE2A8295DQ37119023-043BE938-0C8B-42F6-AF39-4CDF7AD43CD3Q37344532-48F17A6D-9BD5-47B5-A09A-59E024FBFA30Q37650317-D846AC2D-B158-4686-AF95-26450BE2EF9EQ37657464-33D2FF59-DEF6-4F43-9DEA-214AC8B2654DQ37701894-493762A9-70D9-4511-BE0A-BDFD865BCE7EQ37866827-ACADE33B-91BF-4987-81E4-C0750D2C006CQ38060894-7BBA80EF-2957-4EE0-A173-30BBF8306A21Q38178526-666B3F56-8902-4718-9355-D3F8C51874CAQ38264086-48A10750-4FF1-48B9-A7ED-15082276C9FDQ38686517-26EAB3D0-07EA-47E0-B668-C0369EE73078Q38913554-EA795D72-AB13-471E-90C2-0C80F12F6068Q38948650-E5EDA5C9-34EC-4341-8E4E-1A609BC49E36Q39328808-AE0BD719-B90D-4C3C-A846-DA4E3D6DE72AQ39932430-098A8078-0CEE-4D55-9CF7-5307B24CB3ECQ40210434-A3CAAE82-1420-463F-9410-4DC5FA098E0EQ40303429-0809EB75-A245-4E97-BB77-6CF5B6F5DF25Q43137240-F23A5847-66CF-423D-BD01-ACD97BC484A8Q43975147-7AAC4275-B3D7-4993-92F9-2B61F41D8C83Q44506237-90447B95-E0E6-40CB-A8D8-E5365983B5B1Q44558731-6A787681-AC4F-4BAD-8DE4-1E1B03461292Q46407263-4D5CDAA5-F2D4-4312-8633-457831A469FAQ47274881-D3A24B24-2560-4B71-B8E4-1296388C7F21Q50019528-4F1C8B50-A66E-475D-9E54-AEE29589574AQ51617424-045D9848-FED8-4177-80BC-CB7DDA16C412
P2860
A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
A double-blind trial on prophy ...... e myelogenous leukaemia (AML).
@en
type
label
A double-blind trial on prophy ...... e myelogenous leukaemia (AML).
@en
prefLabel
A double-blind trial on prophy ...... e myelogenous leukaemia (AML).
@en
P2093
P50
P921
P1433
P1476
A double-blind trial on prophy ...... e myelogenous leukaemia (AML).
@en
P2093
Andrew J Ullmann
Angelika Böhme
Claus P Heussel
Dorothee Arenz
Gernot Wassmer
Ivonne Drzisga
Jörg J Vehreschild
Margit Hummel
Sabine Mousset
Urs Harnischmacher
P304
P356
10.1016/J.JINF.2007.07.003
P577
2007-09-06T00:00:00Z